This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Aapro, M. S. Articles by Extermann, M. Search for Related Content PubMed PubMed Citation Articles by Aapro, M. S. Articles by Extermann, M.

Original Paper Geriatric Oncology

Never Too Old? Age Should Not Be a Barrier to Enrollment in Cancer Clinical Trials

^a Institut Multidisciplinaire d’Oncologie, Genolier, Switzerland; ^b Department of Medical Oncology, University Dresden, Dresden, Germany; ^c Center on Aging, Duke University and GRECC, VAMC, Durham, North Carolina, USA; ^d H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA

Correspondence: Matti S. Aapro, M.D., Institut Multidisciplinaire d’Oncologie, CH-1272 Genolier, Switzerland. Telephone: 41-22-366-9135; Fax: 41-22-366-9131; e-mail: MAAPRO{at}genolier.net

Throughout Europe and the U.S., over 60% of the total incidence of cancer occurs in the elderly (65 years) population, a patient group that requires particular consideration when making treatment decisions due to a number of factors. Despite this, elderly patients are generally under-represented in clinical trials such that study data should be interpreted with caution because results in younger cancer patients may not always extrapolate to the typical elderly cancer patient.

Reports suggest that elderly cancer patients represent around 22% of patients enrolled in phase II clinical studies. Barriers to the accrual of elderly patients to clinical trials include lack of appropriate trials, high burden of comorbidity, study-imposed restrictions, and attitudes of physicians. There is a belief that elderly patients may be unable to tolerate various cancer therapies, which may result in this patient population being excluded from prospective trials. However, clinical data demonstrate that age alone is not a sufficient reason to withhold treatment.

Lack of clinical trial data and the associated lack of evidence-based guidelines for elderly patients mean physicians have little to guide them, with the result that patients may not receive the optimal therapy. As clinical trials are the primary method of evaluating the efficacy and safety of adjuvant and palliative cancer therapies, trials that specifically target the elderly cancer patient are required to adequately assess the risks and benefits of treatment in this vulnerable population. This review aims to assess the clinical reality and clinical trial age mismatch to evaluate implications for elderly cancer patients and to identify how this situation may be addressed. Possible reasons for the disparity, and the resulting clinical consequences, are also considered.

Key Words. Elderly • Clinical trials • Cancer • 5-HT₃-receptor antagonists

This article has been cited by other articles:

				D. Papamichael, R. Audisio, J.-C. Horiot, B. Glimelius, J. Sastre, E. Mitry, E. Van Cutsem, M. Gosney, C.-H. Kohne, and M. Aapro Treatment of the elderly colorectal cancer patient: SIOG expert recommendations Ann. Onc., January 1, 2009; 20(1): 5 - 16. [Abstract] [Full Text] [PDF]

				T. McKibbin, C. R. Frei, R. E. Greene, P. Kwan, J. Simon, and J. M. Koeller Disparities in the Use of Chemotherapy and Monoclonal Antibody Therapy for Elderly Advanced Colorectal Cancer Patients in the Community Oncology Setting Oncologist, August 1, 2008; 13(8): 876 - 885. [Abstract] [Full Text] [PDF]

				H. J. Cohen Overturning Barriers Will Take Heavy Lifting J. Oncol. Pract, July 1, 2008; 4(4): 169 - 170. [Full Text] [PDF]

				N. L. Keating, M. B. Landrum, C. N. Klabunde, R. H. Fletcher, S. O. Rogers, W. R. Doucette, D. Tisnado, S. Clauser, and K. L. Kahn Adjuvant Chemotherapy for Stage III Colon Cancer: Do Physicians Agree About the Importance of Patient Age and Comorbidity? J. Clin. Oncol., May 20, 2008; 26(15): 2532 - 2537. [Abstract] [Full Text] [PDF]

				M. E. Ford, S. L. Havstad, M. E. Fields, B. Manigo, B. McClary, and L. Lamerato Effects of Baseline Comorbidities on Cancer Screening Trial Adherence among Older African American Men Cancer Epidemiol. Biomarkers Prev., May 1, 2008; 17(5): 1234 - 1239. [Abstract] [Full Text] [PDF]

				L. Balducci, H. Al-Halawani, V. Charu, J. Tam, S. Shahin, L. Dreiling, and W. B. Ershler Elderly Cancer Patients Receiving Chemotherapy Benefit from First-Cycle Pegfilgrastim Oncologist, December 1, 2007; 12(12): 1416 - 1424. [Abstract] [Full Text] [PDF]

				C. Terret, G. B. Zulian, A. Naiem, and G. Albrand Multidisciplinary Approach to the Geriatric Oncology Patient J. Clin. Oncol., May 10, 2007; 25(14): 1876 - 1881. [Abstract] [Full Text] [PDF]

				U Basso, L Fratino, A Brunello, F Lumachi, G. De Salvo, S Lonardi, C Ghiotto, H Koussis, L. Pasetto, and S Monfardini Which benefit from adding gemcitabine to vinorelbine in elderly (>=70 years) women with metastatic breast cancer? Early interruption of a phase II study Ann. Onc., January 1, 2007; 18(1): 58 - 63. [Abstract] [Full Text] [PDF]

				M. J. Hassett, A. J. O'Malley, J. R. Pakes, J. P. Newhouse, and C. C. Earle Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst, August 16, 2006; 98(16): 1108 - 1117. [Abstract] [Full Text] [PDF]